Knowledge Hub
Knowledge Hub
Minister of Health Hon Andrew Little officially launched the new PRRT service for New Zealand neuroendocrine cancer patients in July 2021.
Minister of Health, Hon Andrew Little, officially launched the new PRRT (Peptide Receptor Radionuclide Therapy) service for New Zealand neuroendocrine cancer patients on 14 July 2021.
In 2017, PHARMAC considered Unicorn Foundation NZ's PRRT funding submission. Concern at the continued delays in setting up PRRT led Unicorn Foundation to advocate for High Cost Treatment Pool funding.
In 2020 COVID-19 in Melbourne saw the Victorian state borders closed, so New Zealand NET patients could no longer access PRRT in Melbourne. Unicorn Foundation NZ was involved in the urgent work that followed to establish a permanent PRRT service at Auckland City Hospital — finally launched in 2021.
And now, we have PRRT as a permanent service for New Zealand patients.
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.